Many investors think of AI as a story about chips, software, and the companies building the technology. But its biggest impact may be far broader than that. My colleague Louis Navellier has been exploring how the same deep-learning systems that are accelerating breakthroughs in medicine, scientific research, and drug discovery could also transform the way investors identify opportunities in the stock market.

Many investors think of AI as a story about chips, software, and the companies building the technology. But its biggest impact may be far broader than that. My colleague Louis…

The AI rewriting medicine is the same AI now applied to 47 years of quant investing data — and the backtested results are extraordinary.